https://news.medxy.ai/zh/81153-2/Medxy AIzh2026-10-06T07:08:11-07:00影响NAION视功能恶化的早期视神经乳头水肿速度：基于循证医学的综述 https://news.medxy.ai/ja/naion-optic-nerve-swelling/Medxy AIja2026-10-06T07:07:48-07:00NAIONの視機能悪化を左右する早期視神経乳頭腫脹速度：エビデンスに基づく総説 https://news.medxy.ai/vi/optic-nerve-conduction-speed/Medxy AIvi2026-10-06T07:07:22-07:00Tốc độ phù đầu dây thần kinh thị giác sớm liên quan với suy giảm thị lực trong bệnh lý thần kinh thị giác thiếu máu cục bộ trước không do động mạch: Tổng quan dựa trên bằng chứng https://news.medxy.ai/early-optic-nerve-head-swelling-rate-correlates-with-visual-decline-in-nonarteritic-anterior-ischemic-optic-neuropathy-an-evidence-based-review/Medxy AIen2026-10-06T07:06:59-07:00Early Optic Nerve Head Swelling Rate Correlates with Visual Decline in Nonarteritic Anterior Ischemic Optic Neuropathy: An Evidence-Based Review https://news.medxy.ai/zh/cetp-inhibition-benefits-risks/Medxy AIzh2026-10-06T07:06:13-07:00CETP抑制：心血管获益与年龄相关性黄斑变性风险之间的“双刃剑” https://news.medxy.ai/ja/cetp-inhibition-risk/Medxy AIja2026-10-06T07:05:50-07:00CETP阻害は心血管保護か、網膜リスクか：加齢黄斑変性をめぐる遺伝学的検証 https://news.medxy.ai/vi/cetp-inhibition-tradeoff/Medxy AIvi2026-10-06T07:05:29-07:00Ức chế CETP: “con dao hai lưỡi” giữa lợi ích tim mạch và nguy cơ thoái hóa hoàng điểm do tuổi tác https://news.medxy.ai/cholesteryl-ester-transfer-protein-inhibition-a-double-edged-sword-in-cardiovascular-health-and-age-related-macular-degeneration-risk/Medxy AIen2026-10-06T07:05:08-07:00Cholesteryl Ester Transfer Protein Inhibition: A Double-Edged Sword in Cardiovascular Health and Age-Related Macular Degeneration Risk https://news.medxy.ai/zh/remote-eye-pressure-monitoring-2/Medxy AIzh2026-10-06T07:04:31-07:00远程监测眼压与新型阈值指标，可预测治疗中开角型青光眼的视野进展 https://news.medxy.ai/vi/remote-intraocular-pressure/Medxy AIvi2026-10-06T07:03:50-07:00Theo dõi áp lực nội nhãn từ xa và các chỉ số ngưỡng mới dự đoán tiến triển thị trường ở glaucoma góc mở đã điều trị https://news.medxy.ai/remote-intraocular-pressure-monitoring-and-novel-threshold-metrics-predict-visual-field-progression-in-treated-open-angle-glaucoma/Medxy AIen2026-10-06T07:03:28-07:00Remote Intraocular Pressure Monitoring and Novel Threshold Metrics Predict Visual Field Progression in Treated Open-Angle Glaucoma https://news.medxy.ai/zh/81121-2/Medxy AIzh2026-10-06T07:02:51-07:00头颈部癌放疗后的长期阿片类药物使用：患病率、风险因素及临床意义 https://news.medxy.ai/ja/opioid-use-head-neck-cancer/Medxy AIja2026-10-06T07:02:30-07:00頭頸部癌の放射線治療後に長引くオピオイド使用：有病率・リスク因子・臨床的意義 https://news.medxy.ai/vi/long-term-opioid-use/Medxy AIvi2026-10-06T07:02:07-07:00Sử dụng opioid kéo dài sau xạ trị ở ung thư đầu và cổ: Tỷ lệ hiện mắc, yếu tố nguy cơ và ý nghĩa lâm sàng https://news.medxy.ai/long-term-opioid-use-after-radiation-therapy-in-head-and-neck-cancer-prevalence-risk-factors-and-clinical-implications/Medxy AIen2026-10-06T07:01:46-07:00Long-Term Opioid Use After Radiation Therapy in Head and Neck Cancer: Prevalence, Risk Factors, and Clinical Implications https://news.medxy.ai/zh/testosterone-suppression-cancer-risk/Medxy AIzh2026-10-06T07:01:12-07:00抑制睾酮或可降低男性喉癌与下咽癌风险：来自瑞典大型队列的研究发现 https://news.medxy.ai/ja/81111-2/Medxy AIja2026-10-06T07:00:54-07:00テストステロンの抑制が男性の喉頭がん・下咽頭がんのリスクを低減させる可能性 https://news.medxy.ai/vi/testosterone-inhibition-cancer-risk/Medxy AIvi2026-10-06T07:00:34-07:00Ức chế testosterone có liên quan đến giảm nguy cơ ung thư biểu mô tế bào vảy thanh quản và hạ họng ở nam giới: Góc nhìn từ một đoàn hệ lớn tại Thụy Điển https://news.medxy.ai/testosterone-inhibition-and-reduced-risk-of-laryngeal-and-hypopharyngeal-squamous-cell-carcinoma-in-men-insights-from-a-large-swedish-cohort/Medxy AIen2026-10-06T07:00:14-07:00Testosterone Inhibition and Reduced Risk of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma in Men: Insights from a Large Swedish Cohort https://news.medxy.ai/zh/salivary-gland-tumor-diagnosis/Medxy AIzh2026-10-06T06:59:38-07:00大唾液腺肿瘤诊断的新进展：粗针穿刺活检的临床价值 https://news.medxy.ai/ja/81099-2/Medxy AIja2026-10-06T06:59:19-07:00大唾液腺腫瘍診断の新たな進展：太い針による穿刺生検の臨床的意義 https://news.medxy.ai/vi/salivary-gland-biopsy/Medxy AIvi2026-10-06T06:59:00-07:00Nâng cao chẩn đoán u tuyến nước bọt lớn: Giá trị lâm sàng của sinh thiết kim lõi https://news.medxy.ai/advancing-diagnosis-of-major-salivary-gland-tumors-the-clinical-value-of-core-needle-biopsy/Medxy AIen2026-10-06T06:58:39-07:00Advancing Diagnosis of Major Salivary Gland Tumors: The Clinical Value of Core Needle Biopsy https://news.medxy.ai/zh/bone-healing-factors/Medxy AIzh2026-10-06T06:58:06-07:00骨愈合是否关键？骨性微血管中面部重建结局的影响因素分析 https://news.medxy.ai/ja/bone-healing-impact/Medxy AIja2026-10-06T06:57:45-07:00骨癒合は転帰に影響するのか：骨性マイクロバスキュラー中顔面再建における検討 https://news.medxy.ai/vi/bone-healing-impact-2/Medxy AIvi2026-10-06T06:57:23-07:00Đánh giá ảnh hưởng của sự liền xương đối với kết quả tái tạo tầng giữa mặt bằng vạt vi phẫu xương https://news.medxy.ai/evaluating-the-impact-of-bony-union-on-outcomes-in-osseous-microvascular-midface-reconstruction/Medxy AIen2026-10-06T06:57:01-07:00Evaluating the Impact of Bony Union on Outcomes in Osseous Microvascular Midface Reconstruction https://news.medxy.ai/zh/fungal-sinusitis-differentiation/Medxy AIzh2026-10-06T06:56:25-07:00从结构化组织病理学看沙特队列中变应性真菌性鼻-鼻窦炎与嗜酸性粒细胞性伴鼻息肉慢性鼻-鼻窦炎的鉴别 https://news.medxy.ai/ja/eosinophilic-sinusitis/Medxy AIja2026-10-06T06:56:04-07:00アレルギー性真菌性鼻副鼻腔炎と鼻茸を伴う好酸球性慢性鼻副鼻腔炎の鑑別：サウジアラビア・コホートにおける構造化病理組織学からの知見 https://news.medxy.ai/vi/allergic-fungal-vs-eosinophilic-sinusitis/Medxy AIvi2026-10-06T06:55:43-07:00Phân biệt viêm mũi xoang do nấm dị ứng với viêm mũi xoang mạn tính tăng bạch cầu ái toan có polyp mũi: góc nhìn từ mô bệnh học có cấu trúc trên một đoàn hệ Saudi Arabia https://news.medxy.ai/differentiating-allergic-fungal-rhinosinusitis-from-eosinophilic-chronic-rhinosinusitis-with-nasal-polyps-insights-from-structured-histopathology-in-a-saudi-cohort/Medxy AIen2026-10-06T06:55:22-07:00Differentiating Allergic Fungal Rhinosinusitis from Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: Insights from Structured Histopathology in a Saudi Cohort https://news.medxy.ai/ja/appendiceal-abscess-management/Medxy AIja2026-10-06T06:54:46-07:00虫垂膿瘍をどう扱うか――2025年イタリア・コンセンサスが示す実践的フレームワーク https://news.medxy.ai/vi/appendix-abscess-management/Medxy AIvi2026-10-06T06:54:11-07:00Áp-xe ruột thừa: Khung xử trí thực hành dựa trên sinh lý học từ Đồng thuận Ý 2025 https://news.medxy.ai/zh/81074-2/Medxy AIzh2026-10-06T06:53:38-07:00如何处理阑尾脓肿——2025年意大利共识提出的实践框架 https://news.medxy.ai/a-practical-physiology-driven-framework-for-appendiceal-abscess-key-recommendations-from-the-2025-italian-consensus/Medxy AIen2026-10-06T06:53:08-07:00A Practical, Physiology-Driven Framework for Appendiceal Abscess: Key Recommendations from the 2025 Italian Consensus https://news.medxy.ai/zh/frailty-predicts-outcomes/Medxy AIzh2026-10-06T06:52:05-07:00超越年龄：虚弱比实际年龄更能预测老年患者术后结局 https://news.medxy.ai/ja/beyond-age-frailty/Medxy AIja2026-10-06T06:51:47-07:00年齢を超えて：高齢者の術後転帰を最もよく予測するのはフレイル https://news.medxy.ai/vi/age-frailty-surgery/Medxy AIvi2026-10-06T06:51:24-07:00Vượt qua tuổi tác: Suy yếu là yếu tố dự đoán vượt trội về kết cục sau phẫu thuật ở người cao tuổi https://news.medxy.ai/beyond-age-frailty-as-a-superior-predictor-of-postoperative-outcomes-in-older-adults/Medxy AIen2026-10-06T06:51:03-07:00Beyond Age: Frailty as a Superior Predictor of Postoperative Outcomes in Older Adults https://news.medxy.ai/zh/aldo-renin-ratio-threshold/Medxy AIzh2026-10-06T06:50:27-07:00优化醛固酮/肾素比值阈值：提高正常醛固酮水平患者原发性醛固酮增多症的检出率 https://news.medxy.ai/ja/aldosterone-renin-ratio-2/Medxy AIja2026-10-06T06:50:04-07:00原発性アルドステロン症の拾い上げを高める：アルドステロン／レニン比の閾値再検討 https://news.medxy.ai/vi/aldosterone-renin-ratio-3/Medxy AIvi2026-10-06T06:49:39-07:00Hiệu chỉnh ngưỡng tỷ lệ aldosterone trên renin: Nâng cao phát hiện cường aldosterone tiên phát ở bệnh nhân có nồng độ aldosterone bình thường https://news.medxy.ai/refining-aldosterone-to-renin-ratio-thresholds-improving-detection-of-primary-aldosteronism-in-patients-with-normal-aldosterone-levels/Medxy AIen2026-10-06T06:49:14-07:00Refining Aldosterone-to-Renin Ratio Thresholds: Improving Detection of Primary Aldosteronism in Patients with Normal Aldosterone Levels https://news.medxy.ai/zh/racial-disparities-trauma-care/Medxy AIzh2026-10-06T06:48:35-07:00创伤患者院前救治中的种族差异：基于证据的综述 https://news.medxy.ai/ja/racial-disparities-prehospital-care/Medxy AIja2026-10-06T06:48:13-07:00受傷患者の病院前介入における人種差：エビデンスに基づく総説 https://news.medxy.ai/vi/81049-2/Medxy AIvi2026-10-06T06:47:49-07:00Chênh lệch về chủng tộc trong chăm sóc tiền bệnh viện cho bệnh nhân chấn thương: Tổng quan dựa trên bằng chứng https://news.medxy.ai/racial-disparities-in-prehospital-interventions-among-injured-patients-an-evidence-based-review/Medxy AIen2026-10-06T06:47:27-07:00Racial Disparities in Prehospital Interventions Among Injured Patients: An Evidence-Based Review https://news.medxy.ai/zh/81039-2/Medxy AIzh2026-10-06T06:46:32-07:00良性及低级别胰头肿瘤：肿瘤剜除术与胰十二指肠切除术的当代证据综合分析 https://news.medxy.ai/ja/benign-pancreatic-tumor-surgery/Medxy AIja2026-10-06T06:46:05-07:00良性・低悪性度膵頭部腫瘍に対する核出術と膵頭十二指腸切除術：最新エビデンスの総括 https://news.medxy.ai/vi/tumor-removal-options/Medxy AIvi2026-10-06T06:45:41-07:00Bóc nhân khối u hay cắt tá tràng – tụy: lựa chọn nào tối ưu cho khối u lành tính và độ thấp ở đầu tụy? https://news.medxy.ai/enucleation-vs-pancreatoduodenectomy-for-benign-and-low-grade-pancreatic-head-tumors-a-contemporary-evidence-synthesis/Medxy AIen2026-10-06T06:45:15-07:00Enucleation vs Pancreatoduodenectomy for Benign and Low-Grade Pancreatic Head Tumors: A Contemporary Evidence Synthesis https://news.medxy.ai/zh/robot-assisted-vs-thoracoscopic/Medxy AIzh2026-10-06T06:44:26-07:00机器人辅助还是胸腹腔镜？食管癌手术精准度的进一步提升 https://news.medxy.ai/ja/robotic-surgery-advances/Medxy AIja2026-10-06T06:44:06-07:00ロボット手術は胸腹腔鏡手術を上回るか？　食道癌治療における精密外科の新展開 https://news.medxy.ai/vi/robotic-esophagectomy/Medxy AIvi2026-10-06T06:43:41-07:00Phẫu thuật cắt thực quản bằng robot hay thoracolaparoscopic: Nâng cao độ chính xác trong điều trị ung thư thực quản https://news.medxy.ai/robotic-vs-thoracolaparoscopic-esophagectomy-advancing-surgical-precision-in-esophageal-cancer-treatment/Medxy AIen2026-10-06T06:43:19-07:00Robotic vs Thoracolaparoscopic Esophagectomy: Advancing Surgical Precision in Esophageal Cancer Treatment https://news.medxy.ai/zh/medicaid-expansion-survival/Medxy AIzh2026-10-06T06:42:39-07:00Medicaid扩展对结直肠癌肝转移患者生存的影响：基于人群的分析 https://news.medxy.ai/ja/81014-2/Medxy AIja2026-10-06T06:42:21-07:00メディケイドの拡大が結腸直腸癌の肝転移患者の生存に及ぼす影響 https://news.medxy.ai/vi/81013-2/Medxy AIvi2026-10-06T06:41:58-07:00Tác động của việc mở rộng Medicaid đến tỷ lệ sống còn ở bệnh nhân ung thư đại trực tràng di căn gan https://news.medxy.ai/impact-of-medicaid-expansion-on-survival-in-colorectal-cancer-with-liver-metastasis-a-population-based-analysis/Medxy AIen2026-10-06T06:41:35-07:00Impact of Medicaid Expansion on Survival in Colorectal Cancer with Liver Metastasis: A Population-Based Analysis https://news.medxy.ai/zh/81006-2/Medxy AIzh2026-10-06T06:40:58-07:00针对肝细胞癌的肝移植：完全病理学缓解对预后的影响及治疗方案的差异——基于美国全国数据库的研究 https://news.medxy.ai/ja/liver-transplant-outcomes/Medxy AIja2026-10-06T06:40:34-07:00肝細胞癌に対する肝移植：完全病理学的奏効の予後への影響と治療法の差異―米国全国データベース研究 https://news.medxy.ai/vi/81000-2/Medxy AIvi2026-10-06T06:40:07-07:00Ghép gan điều trị ung thư biểu mô tế bào gan: Ảnh hưởng của đáp ứng bệnh học hoàn toàn đến tiên lượng và sự khác biệt về phương pháp điều trị – Nghiên cứu dựa trên cơ sở dữ liệu toàn quốc của Hoa Kỳ https://news.medxy.ai/liver-transplantation-hcc/Medxy AIen2026-10-06T06:39:42-07:00Liver Transplantation for Hepatocellular Carcinoma: Prognostic Impact of Complete Pathologic Response and Influence of Treatment Modality—A US National Database Study https://news.medxy.ai/zh/robot-assisted-esophagectomy/Medxy AIzh2026-10-06T06:38:48-07:00机器人辅助食管切除术：重塑食管癌外科治疗的新标杆 https://news.medxy.ai/ja/robotic-esophagectomy-guide/Medxy AIja2026-10-06T06:38:31-07:00食道癌手術の新たな指標を築くロボット支援食道切除術 https://news.medxy.ai/vi/robot-assisted-esophagectomy-2/Medxy AIvi2026-10-06T06:38:11-07:00Cắt thực quản hỗ trợ robot: Nâng tầm chuẩn mực phẫu thuật trong chăm sóc ung thư thực quản https://news.medxy.ai/robotic-assisted-esophagectomy-transforming-surgical-benchmarks-in-esophageal-cancer-care/Medxy AIen2026-10-06T06:37:53-07:00Robotic-Assisted Esophagectomy: Transforming Surgical Benchmarks in Esophageal Cancer Care https://news.medxy.ai/zh/80981-2/Medxy AIzh2026-10-06T06:37:21-07:00评估帕博利珠单抗、贝伐珠单抗联合口服节律性环磷酰胺治疗经多线治疗的铂耐药卵巢癌：真实世界疗效与临床启示 https://news.medxy.ai/ja/platinum-resistant-ovarian-cancer-treatment/Medxy AIja2026-10-06T06:36:58-07:00多治療歴プラチナ抵抗性卵巣癌に対するペムブロリズマブ・ベバシズマブ・経口メトロノミック・シクロホスファミドの評価：実臨床成績と臨床的示唆 https://news.medxy.ai/vi/80975-2/Medxy AIvi2026-10-06T06:36:33-07:00Phối hợp pembrolizumab, bevacizumab và cyclophosphamide đường uống theo phác đồ metronomic cho ung thư buồng trứng kháng platin đã trải qua nhiều đợt điều trị trước đó https://news.medxy.ai/evaluating-pembrolizumab-bevacizumab-and-oral-metronomic-cyclophosphamide-in-heavily-pretreated-platinum-resistant-ovarian-cancer-real-world-outcomes-and-clinical-implications/Medxy AIen2026-10-06T06:36:07-07:00Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications https://news.medxy.ai/zh/endometrial-cancer-genetics/Medxy AIzh2026-10-06T06:35:23-07:00子宫内膜癌的遗传学检测：致病性胚系变异的流行率及其对临床实践的启示 https://news.medxy.ai/ja/80962-2/Medxy AIja2026-10-06T06:35:02-07:00子宮内膜癌の遺伝学的検査：病原性生殖細胞系列変異の有病率と臨床診療への示唆 https://news.medxy.ai/vi/80961-2/Medxy AIvi2026-10-06T06:34:42-07:00Xét nghiệm di truyền ung thư nội mạc tử cung: Tỷ lệ biến thể dòng mầm gây bệnh và ý nghĩa đối với thực hành lâm sàng https://news.medxy.ai/genetic-testing-in-endometrial-cancer-prevalence-of-pathogenic-germline-variants-and-implications-for-clinical-practice-in-a-diverse-community-cohort/Medxy AIen2026-10-06T06:34:18-07:00Genetic Testing in Endometrial Cancer: Prevalence of Pathogenic Germline Variants and Implications for Clinical Practice in a Diverse Community Cohort https://news.medxy.ai/zh/elagolix-pain-relief/Medxy AIzh2026-10-06T06:33:44-07:00III期多中心试验证实：elagolix缓解中重度子宫内膜异位症疼痛不劣于dienogest https://news.medxy.ai/ja/elagolix-vs-dienogest/Medxy AIja2026-10-06T06:33:20-07:00中等度〜重度子宮内膜症疼痛に対するElagolixとDienogestの有効性・安全性比較：第III相多施設試験からの知見 https://news.medxy.ai/vi/elagolix-dienogest-comparison/Medxy AIvi2026-10-06T06:32:56-07:00Elagolix hay dienogest: so sánh hiệu quả và độ an toàn trong giảm đau lạc nội mạc tử cung mức độ trung bình đến nặng từ thử nghiệm đa trung tâm giai đoạn III https://news.medxy.ai/comparative-efficacy-and-safety-of-elagolix-versus-dienogest-in-moderate-to-severe-endometriosis-pain-insights-from-a-phase-iii-multicentric-trial/Medxy AIen2026-10-06T06:32:33-07:00Comparative Efficacy and Safety of Elagolix Versus Dienogest in Moderate-to-Severe Endometriosis Pain: Insights from a Phase III Multicentric Trial https://news.medxy.ai/zh/perineal-injury-effects/Medxy AIzh2026-10-06T06:31:54-07:00二度会阴裂伤与会阴切开术后伤口并发症对盆底症状的长期影响：REPAIR研究带来的启示 https://news.medxy.ai/ja/pelvic-floor-symptoms/Medxy AIja2026-10-06T06:31:33-07:00第二度会陰裂傷・会陰切開後の骨盤底症状に対する創傷合併症の長期的影響：REPAIR研究からの知見 https://news.medxy.ai/vi/long-term-wound-effects/Medxy AIvi2026-10-06T06:31:13-07:00Ảnh hưởng lâu dài của biến chứng vết thương đến triệu chứng sàn chậu sau rách tầng sinh môn độ 2 và episiotomy: phát hiện từ nghiên cứu REPAIR https://news.medxy.ai/long-term-impact-of-wound-complications-on-pelvic-floor-symptoms-following-second-degree-tears-and-episiotomy-insights-from-the-repair-study/Medxy AIen2026-10-06T06:30:52-07:00Long-Term Impact of Wound Complications on Pelvic Floor Symptoms Following Second-Degree Tears and Episiotomy: Insights from the REPAIR Study https://news.medxy.ai/zh/obgyn-ai-competency/Medxy AIzh2026-10-06T06:30:14-07:00妇产科临床AI胜任力：在创新与患者安全、责任之间寻求平衡 https://news.medxy.ai/ja/obgyn-ai-competence/Medxy AIja2026-10-06T06:29:58-07:00産科・婦人科における臨床AIコンピテンス：革新と患者安全・説明責任の両立 https://news.medxy.ai/vi/ai-clinical-capacity/Medxy AIvi2026-10-06T06:29:38-07:00Năng lực lâm sàng về AI trong sản khoa và phụ khoa: Cân bằng giữa đổi mới, an toàn người bệnh và trách nhiệm giải trình https://news.medxy.ai/clinical-ai-competence-in-obstetrics-and-gynecology-balancing-innovation-with-patient-safety-and-accountability/Medxy AIen2026-10-06T06:29:19-07:00Clinical AI Competence in Obstetrics and Gynecology: Balancing Innovation with Patient Safety and Accountability https://news.medxy.ai/zh/early-adult-granulosa-tumor/Medxy AIzh2026-10-06T06:28:43-07:00早期成人颗粒细胞瘤的保留卵巢手术：生存结局不劣于双侧卵巢切除术 https://news.medxy.ai/ja/early-adult-granulosa-cell-tumor/Medxy AIja2026-10-06T06:28:21-07:00早期成人型顆粒膜細胞腫に対する卵巣温存手術：両側卵巣摘出術に匹敵する生存成績 https://news.medxy.ai/vi/ovarian-conservation-surgery/Medxy AIvi2026-10-06T06:28:00-07:00Phẫu thuật bảo tồn buồng trứng ở u tế bào hạt trưởng thành giai đoạn sớm: Kết cục sống còn tương đương cắt buồng trứng hai bên https://news.medxy.ai/ovarian-sparing-surgery-in-early-stage-adult-granulosa-cell-tumors-comparable-survival-outcomes-to-bilateral-oophorectomy/Medxy AIen2026-10-06T06:27:39-07:00Ovarian-Sparing Surgery in Early-Stage Adult Granulosa Cell Tumors: Comparable Survival Outcomes to Bilateral Oophorectomy https://news.medxy.ai/zh/carrier-screening-insights/Medxy AIzh2026-10-06T06:26:59-07:00优化携带者筛查：来自母胎医学实践的洞见与建议 https://news.medxy.ai/ja/80913-2/Medxy AIja2026-10-06T06:26:39-07:00保因者スクリーニングの最適化：母体胎児医学の実践から得られる知見と提言 https://news.medxy.ai/vi/80911-2/Medxy AIvi2026-10-06T06:26:19-07:00Tối ưu hóa Sàng lọc Người mang gen bệnh: Những hiểu biết và khuyến nghị từ thực tiễn Y học Bà mẹ – Thai nhi https://news.medxy.ai/optimizing-carrier-screening-insights-and-recommendations-from-a-maternal-fetal-medicine-practice/Medxy AIen2026-10-06T06:25:58-07:00Optimizing Carrier Screening: Insights and Recommendations From a Maternal-Fetal Medicine Practice https://news.medxy.ai/zh/lichen-sclerosus-treatment/Medxy AIzh2026-10-06T06:25:20-07:00外阴硬化性苔藓治疗新进展：CO2 激光与外用丙酸氯倍他索的疗效比较 https://news.medxy.ai/ja/vulvar-lichen-sclerosus-treatment/Medxy AIja2026-10-06T06:24:59-07:00外陰部硬化性苔癬に対するCO2レーザーと外用クロベタゾールの比較：症状管理を変える新知見 https://news.medxy.ai/vi/co2-laser-vs-clobetasol/Medxy AIvi2026-10-06T06:24:40-07:00So sánh liệu pháp laser CO2 với clobetasol bôi trong lichen sclerosus âm hộ: Bước tiến mới trong kiểm soát triệu chứng https://news.medxy.ai/comparing-co2-laser-therapy-and-topical-clobetasol-in-vulvar-lichen-sclerosus-breakthroughs-in-symptom-management/Medxy AIen2026-10-06T06:24:19-07:00Comparing CO2 Laser Therapy and Topical Clobetasol in Vulvar Lichen Sclerosus: Breakthroughs in Symptom Management https://news.medxy.ai/patient-specific-pessaries-after-suboptimal-outcomes-with-standard-pessary-use-a-multicenter-retrospective-case-series/Medxy AIen2026-10-06T06:23:45-07:00Patient-Specific Pessaries After Suboptimal Outcomes With Standard Pessary Use: A Multicenter Retrospective Case Series https://news.medxy.ai/zh/tesera-liver-cancer/Medxy AIzh2026-10-06T06:23:10-07:00TESERA：基于 H&E 全视野切片推动肝细胞癌形态学分型与预后分层 https://news.medxy.ai/ja/heslides-hepatocellular-carcinoma-subtypes/Medxy AIja2026-10-06T06:22:49-07:00H&E全スライド画像から肝細胞癌の形態学的サブタイプと予後を読み解くTESERA https://news.medxy.ai/tesera-advancing-morphologic-subtyping-and-prognostic-stratification-in-hepatocellular-carcinoma-using-he-whole-slide-images/Medxy AIen2026-10-06T06:22:01-07:00TESERA: Advancing Morphologic Subtyping and Prognostic Stratification in Hepatocellular Carcinoma Using H&E Whole-Slide Images https://news.medxy.ai/exceptional-and-durable-response-to-selpercatinib-in-a-patient-with-apparently-ret-negative-hras-and-nf1-mutated-metastatic-medullary-thyroid-carcinoma/Medxy AIen2026-10-06T06:03:01-07:00Exceptional and Durable Response to Selpercatinib in a Patient with Apparently RET-Negative, HRAS-, and NF1-Mutated Metastatic Medullary Thyroid Carcinoma https://news.medxy.ai/zh/80880-2/Medxy AIzh2026-10-05T06:21:25-07:00为期8周的Bemnifosbuvir-Ruzasvir疗法：治疗慢性丙型肝炎疗效高且耐受性良好 https://news.medxy.ai/ja/80879-2/Medxy AIja2026-10-05T06:21:03-07:00ベムニフォスブビル・ルザスビル8週間投与レジメン：慢性C型肝炎における高い有効性と良好な忍容性 https://news.medxy.ai/vi/bemnifosbuvir-ruzasvir-8-weeks/Medxy AIvi2026-10-05T06:20:38-07:00Phác đồ Bemnifosbuvir–Ruzasvir 8 Tuần: Hiệu Quả Cao và Dung Nạp Tốt trong Viêm Gan C Mạn https://news.medxy.ai/high-efficacy-and-tolerability-of-an-8-week-bemnifosbuvir-and-ruzasvir-regimen-in-chronic-hepatitis-c-insights-from-a-phase-2-study/Medxy AIen2026-10-05T06:20:17-07:00High Efficacy and Tolerability of an 8-Week Bemnifosbuvir and Ruzasvir Regimen in Chronic Hepatitis C: Insights from a Phase 2 Study https://news.medxy.ai/zh/ctdna-colorectal-cancer/Medxy AIzh2026-10-05T06:19:33-07:00借助循环肿瘤 DNA 识别结直肠癌微小残留病灶：INTERCEPT 计划的研究启示 https://news.medxy.ai/ja/colon-cancer-ctdna/Medxy AIja2026-10-05T06:19:13-07:00大腸癌の微小残存病変検出における循環腫瘍DNAの活用：INTERCEPTプログラムからの知見 https://news.medxy.ai/vi/80873-2/Medxy AIvi2026-10-05T06:18:52-07:00Phát hiện bệnh tồn dư tối thiểu trong ung thư đại trực tràng bằng DNA khối u lưu hành: Những hiểu biết từ chương trình INTERCEPT https://news.medxy.ai/harnessing-circulating-tumour-dna-for-minimal-residual-disease-detection-in-colorectal-cancer-insights-from-the-intercept-programme/Medxy AIen2026-10-05T06:18:29-07:00Harnessing Circulating Tumour DNA for Minimal Residual Disease Detection in Colorectal Cancer: Insights from the INTERCEPT Programme https://news.medxy.ai/an-unexpected-cause-of-severe-steatohepatitis-in-a-young-male/Medxy AIen2026-10-05T06:17:44-07:00An Unexpected Cause of Severe Steatohepatitis in a Young Male https://news.medxy.ai/ja/ems-stroke-guidelines/Medxy AIja2026-10-05T06:17:03-07:00通常EMSにおける院前脳卒中試験の運営・倫理・技術上の優先事項：専門家コンセンサスの解説 https://news.medxy.ai/vi/stroke-trial-priorities/Medxy AIvi2026-10-05T06:16:29-07:00Ưu tiên vận hành, đạo đức và công nghệ cho các thử nghiệm đột quỵ trước viện trong EMS thường quy: Giải thích đồng thuận chuyên gia https://news.medxy.ai/zh/ems-stroke-trial/Medxy AIzh2026-10-05T06:15:49-07:00常规EMS院前卒中试验的操作、伦理与技术优先事项：专家共识解读 https://news.medxy.ai/operational-ethical-and-technological-priorities-for-prehospital-stroke-trials-in-conventional-ems-an-expert-consensus-explained/Medxy AIen2026-10-05T06:15:19-07:00Operational, Ethical, and Technological Priorities for Prehospital Stroke Trials in Conventional EMS: An Expert Consensus Explained https://news.medxy.ai/zh/80863-2/Medxy AIzh2026-10-05T06:14:09-07:00急性缺血性脑卒中患者接受血管内血栓切除术后肌酐水平的连续变化与预后有关 https://news.medxy.ai/ja/creatinine-change-stroke/Medxy AIja2026-10-05T06:13:42-07:00閾値を超えて：急性虚血性脳卒中に対する血管内血栓除去術後の連続的クレアチニン変化と転帰 https://news.medxy.ai/vi/80861-2/Medxy AIvi2026-10-05T06:13:15-07:00Diễn biến nồng độ creatinine liên tục và kết cục lâm sàng sau thủ thuật lấy huyết khối qua đường nội mạch ở bệnh nhân đột quỵ thiếu máu cục bộ cấp tính https://news.medxy.ai/beyond-the-threshold-continuous-creatinine-change-and-outcomes-after-endovascular-thrombectomy-for-acute-ischemic-stroke/Medxy AIen2026-10-05T06:12:46-07:00Beyond the Threshold: Continuous Creatinine Change and Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke https://news.medxy.ai/zh/left-atrial-appendage-occlusion-2/Medxy AIzh2026-10-05T06:11:51-07:00心房颤动卒中预防中左心耳封堵与口服抗凝治疗之比较：最新 Meta 分析 https://news.medxy.ai/ja/80857-2/Medxy AIja2026-10-05T06:11:30-07:00心房細動に伴う脳卒中予防における左心耳閉鎖術と経口抗凝固療法の比較 https://news.medxy.ai/vi/80856-2/Medxy AIvi2026-10-05T06:11:08-07:00So sánh giữa thủ thuật đóng tiểu nhĩ trái và liệu pháp dùng thuốc chống đông đường uống để phòng ngừa đột quỵ ở bệnh nhân rung nhĩ https://news.medxy.ai/evaluating-left-atrial-appendage-closure-versus-oral-anticoagulation-for-stroke-prevention-in-atrial-fibrillation-an-updated-meta-analysis/Medxy AIen2026-10-05T06:10:45-07:00Evaluating Left Atrial Appendage Closure Versus Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: An Updated Meta-Analysis https://news.medxy.ai/zh/tbi-life-support-trends/Medxy AIzh2026-10-05T06:10:04-07:00创伤性脑损伤患者维持生命治疗撤除趋势变化：基于ACS创伤数据十年研究的启示 https://news.medxy.ai/ja/life-support-withdrawal-trends/Medxy AIja2026-10-05T06:09:47-07:00外傷性脳損傷患者における生命維持治療中止の推移：ACS外傷データ10年解析からの示唆 https://news.medxy.ai/vi/tbi-treatment-trends/Medxy AIvi2026-10-05T06:09:21-07:00Xu hướng thay đổi trong việc rút lui điều trị duy trì sự sống ở bệnh nhân chấn thương sọ não: Góc nhìn từ dữ liệu chấn thương ACS trong 10 năm https://news.medxy.ai/evolving-patterns-in-withdrawal-of-life-sustaining-treatment-among-traumatic-brain-injury-patients-insights-from-a-decade-of-acs-trauma-data/Medxy AIen2026-10-05T06:08:58-07:00Evolving Patterns in Withdrawal of Life-Sustaining Treatment Among Traumatic Brain Injury Patients: Insights From a Decade of ACS Trauma Data https://news.medxy.ai/zh/skin-denervation-parkinsons/Medxy AIzh2026-10-05T06:08:18-07:00皮肤去神经支配：连接帕金森病认知下降与脑萎缩的新型生物标志物 https://news.medxy.ai/ja/skin-denervation-parkinson/Medxy AIja2026-10-05T06:07:59-07:00皮膚脱神経はパーキンソン病の認知低下と脳萎縮を示すバイオマーカーとなり得る https://news.medxy.ai/vi/skin-neuropathy-parkinson/Medxy AIvi2026-10-05T06:07:36-07:00Mất chi phối thần kinh ở da: dấu ấn sinh học liên quan đến suy giảm nhận thức và teo não trong bệnh Parkinson https://news.medxy.ai/skin-denervation-as-a-biomarker-linked-to-cognitive-decline-and-brain-atrophy-in-parkinson-disease/Medxy AIen2026-10-05T06:07:13-07:00Skin Denervation as a Biomarker Linked to Cognitive Decline and Brain Atrophy in Parkinson Disease https://news.medxy.ai/zh/car-t-cns-lymphoma/Medxy AIzh2026-10-05T06:06:34-07:00CAR T细胞治疗后，中枢神经系统淋巴瘤患者的中期认知结局：急性神经毒性之外的积极证据 https://news.medxy.ai/ja/car-t-therapy-cns-lymphoma/Medxy AIja2026-10-05T06:06:15-07:00CNSリンパ腫に対するCAR T細胞療法後の中期認知機能：急性神経毒性を超えて見えてきた有望な知見 https://news.medxy.ai/vi/car-t-therapy-lymphoma-3/Medxy AIvi2026-10-05T06:05:53-07:00Sau liệu pháp CAR T ở bệnh nhân u lympho hệ thần kinh trung ương: bằng chứng đáng khích lệ về chức năng nhận thức trung hạn vượt qua độc tính thần kinh cấp tính https://news.medxy.ai/midterm-cognitive-outcomes-after-car-t-cell-therapy-in-cns-lymphoma-patients-encouraging-evidence-beyond-acute-neurotoxicity/Medxy AIen2026-10-05T06:05:30-07:00Midterm Cognitive Outcomes After CAR T-Cell Therapy in CNS Lymphoma Patients: Encouraging Evidence Beyond Acute Neurotoxicity https://news.medxy.ai/zh/sar443820-als-efficacy/Medxy AIzh2026-10-05T06:04:52-07:00SAR443820 在肌萎缩侧索硬化中的疗效评估：来自 HIMALAYA 2 期试验的启示 https://news.medxy.ai/ja/als-ripk1-inhibitor/Medxy AIja2026-10-05T06:04:28-07:00ALSにおけるRIPK1阻害薬SAR443820を評価する：第2相HIMALAYA試験から得られた知見 https://news.medxy.ai/vi/80836-2/Medxy AIvi2026-10-05T06:04:02-07:00Đánh giá thuốc ức chế RIPK1 SAR443820 trong bệnh ALS: Những hiểu biết từ thử nghiệm HIMALAYA giai đoạn 2 https://news.medxy.ai/evaluating-sar443820-a-ripk1-inhibitor-in-amyotrophic-lateral-sclerosis-insights-from-the-phase-2-himalaya-trial/Medxy AIen2026-10-05T06:03:42-07:00Evaluating SAR443820, a RIPK1 Inhibitor, in Amyotrophic Lateral Sclerosis: Insights from the Phase 2 HIMALAYA Trial https://news.medxy.ai/zh/apolipoprotein-j-kidney-damage-2/Medxy AIzh2026-10-05T05:31:44-07:00肝源性载脂蛋白J通过破坏TFEB介导的脂质调控驱动糖尿病肾损伤 https://news.medxy.ai/ja/80827-2/Medxy AIja2026-10-05T05:31:25-07:00肝臓由来アポリポタンパク質Jは、TFEBを介した脂質制御の破綻を通じて糖尿病性腎障害を惹起する https://news.medxy.ai/vi/apolipoprotein-j-kidney-damage/Medxy AIvi2026-10-05T05:31:03-07:00Apolipoprotein J từ gan thúc đẩy tổn thương thận do đái tháo đường qua rối loạn điều hòa lipid trung gian TFEB https://news.medxy.ai/liver-derived-apolipoprotein-j-drives-diabetic-kidney-injury-by-disrupting-tfeb-mediated-lipid-regulation/Medxy AIen2026-10-05T05:30:42-07:00Liver-Derived Apolipoprotein J Drives Diabetic Kidney Injury by Disrupting TFEB-Mediated Lipid Regulation https://news.medxy.ai/zh/empagliflozin-vs-dapagliflozin/Medxy AIzh2026-10-05T05:30:03-07:00Empagliflozin与Dapagliflozin谁更护肝？韩国大队列研究给出答案 https://news.medxy.ai/ja/80815-2/Medxy AIja2026-10-05T05:29:43-07:00エンパグリフロジンとダパグリフロジン、どちらがより肝臓を保護するのか？韓国の大規模コホート研究が答えを提示 https://news.medxy.ai/vi/empagliflozin-vs-dapagliflozin-liver/Medxy AIvi2026-10-05T05:29:21-07:00So sánh trực tiếp empagliflozin và dapagliflozin về kết cục gan ở đái tháo đường type 2 kèm MASLD https://news.medxy.ai/head-to-head-comparison-of-empagliflozin-and-dapagliflozin-on-liver-outcomes-in-type-2-diabetes-with-masld/Medxy AIen2026-10-05T05:28:57-07:00Head-to-Head Comparison of Empagliflozin and Dapagliflozin on Liver Outcomes in Type 2 Diabetes with MASLD https://news.medxy.ai/zh/type-2-diabetes-management/Medxy AIzh2026-10-05T05:17:09-07:002型糖尿病血糖管理再升级：数字疗法联合CGM带来更优结局 https://news.medxy.ai/ja/type-2-diabetes-management-2/Medxy AIja2026-10-05T05:16:49-07:002型糖尿病の血糖管理をさらに前進：CGM併用デジタル治療でより良好な転帰 https://news.medxy.ai/vi/better-blood-sugar-control/Medxy AIvi2026-10-05T05:16:29-07:00Kiểm soát đường huyết tốt hơn ở đái tháo đường type 2: Dược phẩm số phối hợp CGM cho kết quả vượt trội https://news.medxy.ai/enhanced-glycaemic-control-in-type-2-diabetes-digital-therapeutics-combined-with-cgm-show-superior-outcomes/Medxy AIen2026-10-05T05:16:10-07:00Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutics Combined with CGM Show Superior Outcomes https://news.medxy.ai/zh/cabergoline-prolactinoma-treatment/Medxy AIzh2026-10-05T05:15:28-07:00最低泌乳素水平指导的卡麦角林治疗：推动垂体催乳素瘤的持久缓解与安全妊娠 https://news.medxy.ai/ja/cabergoline-treatment/Medxy AIja2026-10-05T05:15:07-07:00最低プロラクチン値に基づくカベルゴリン治療：プロラクチノーマ管理における持続寛解と安全な妊娠の実現 https://news.medxy.ai/vi/cabergoline-prolactin-guided/Medxy AIvi2026-10-05T05:14:49-07:00Cabergoline cá thể hóa theo prolactin đáy: Nâng cao lui bệnh bền vững và an toàn thai kỳ trong điều trị prolactinoma https://news.medxy.ai/nadir-prolactin-guided-cabergoline-therapy-advancing-durable-remission-and-safe-pregnancy-in-prolactinoma-management/Medxy AIen2026-10-05T05:14:25-07:00Nadir Prolactin-Guided Cabergoline Therapy: Advancing Durable Remission and Safe Pregnancy in Prolactinoma Management https://news.medxy.ai/zh/baseline-plasma-metabolites/Medxy AIzh2026-10-05T05:13:47-07:00基线血浆代谢物可预测糖尿病前期长期血糖结局：来自 PROP-ABC 研究的启示 https://news.medxy.ai/ja/prediabetes-metabolites/Medxy AIja2026-10-05T05:13:23-07:00前糖尿病の長期血糖転帰を予測するベースライン血漿代謝物：PROP-ABC研究からの知見 https://news.medxy.ai/vi/plasma-metabolites-prediabetes/Medxy AIvi2026-10-05T05:13:00-07:00Các chất chuyển hóa huyết tương ban đầu dự báo kết cục đường huyết dài hạn ở tiền đái tháo đường: Kết quả từ nghiên cứu PROP-ABC https://news.medxy.ai/baseline-plasma-metabolites-predict-long-term-glycemic-outcomes-in-prediabetes-insights-from-the-prop-abc-study/Medxy AIen2026-10-05T05:12:39-07:00Baseline Plasma Metabolites Predict Long-Term Glycemic Outcomes in Prediabetes: Insights from the PROP-ABC Study https://news.medxy.ai/zh/tirzepatide-cardiovascular-benefits/Medxy AIzh2026-10-05T05:12:01-07:00替尔泊肽心血管获益再解析：基于 REWIND 推算安慰剂的 SURPASS-CVOT 间接比较 https://news.medxy.ai/ja/tirzepatide-cardiovascular-protection/Medxy AIja2026-10-05T05:11:42-07:00Tirzepatideの心血管保護作用を再考する：REWIND補完的プラセボ解析によるSURPASS-CVOTの知見 https://news.medxy.ai/vi/tirzepatide-heart-benefits/Medxy AIvi2026-10-05T05:11:19-07:00Tirzepatide hé lộ lợi ích tim mạch: bằng chứng từ SURPASS-CVOT với phân tích giả dược suy diễn của REWIND https://news.medxy.ai/unveiling-cardiovascular-benefits-of-tirzepatide-insights-from-surpass-cvot-using-imputed-placebo-analysis-of-rewind/Medxy AIen2026-10-05T05:11:00-07:00Unveiling Cardiovascular Benefits of Tirzepatide: Insights from SURPASS-CVOT Using Imputed Placebo Analysis of REWIND https://news.medxy.ai/zh/early-pregnancy-glucose/Medxy AIzh2026-10-05T05:10:22-07:00早孕血糖检测有助于提升妊娠期糖尿病预测：GO MOMs 研究带来新启示 https://news.medxy.ai/ja/gestational-diabetes-prediction/Medxy AIja2026-10-05T05:10:02-07:00妊娠初期の血糖評価で妊娠糖尿病をより高精度に予測：GO MOMs研究からの示唆 https://news.medxy.ai/vi/early-gestational-blood-sugar-test/Medxy AIvi2026-10-05T05:09:39-07:00Xét nghiệm đường huyết sớm trong thai kỳ giúp dự đoán đái tháo đường thai kỳ tốt hơn: Phân tích từ nghiên cứu GO MOMs https://news.medxy.ai/early-pregnancy-glycemic-testing-enhances-gestational-diabetes-prediction-insights-from-the-go-moms-study/Medxy AIen2026-10-05T05:09:18-07:00Early Pregnancy Glycemic Testing Enhances Gestational Diabetes Prediction: Insights from the GO MOMs Study https://news.medxy.ai/zh/80749-2/Medxy AIzh2026-10-05T05:08:39-07:00宫内暴露于母体糖尿病与子代糖尿病风险：原住民与非原住民群体间的差异 https://news.medxy.ai/ja/80748-2/Medxy AIja2026-10-05T05:08:19-07:00母親の糖尿病への子宮内曝露と次世代の糖尿病リスク：ファースト・ネーションズと非ファースト・ネーションズ間の差異 https://news.medxy.ai/vi/maternal-diabetes-exposure-risk/Medxy AIvi2026-10-05T05:07:53-07:00Phơi nhiễm đái tháo đường của mẹ trong tử cung và nguy cơ đái tháo đường ở thế hệ con: khác biệt giữa First Nations và không thuộc First Nations https://news.medxy.ai/in-utero-exposure-to-maternal-diabetes-and-its-impact-on-offspring-diabetes-risk-among-first-nations-and-non-first-nations-populations-a-comprehensive-review/Medxy AIen2026-10-05T05:07:28-07:00In Utero Exposure to Maternal Diabetes and Its Impact on Offspring Diabetes Risk among First Nations and Non-First Nations Populations: A Comprehensive Review https://news.medxy.ai/zh/low-dose-il2-diabetes/Medxy AIzh2026-10-05T05:06:38-07:00新诊断1型糖尿病中的低剂量白细胞介素-2：来自DIABIL-2 2b期试验的启示 https://news.medxy.ai/ja/low-dose-il2-type1-diabetes/Medxy AIja2026-10-05T05:06:22-07:00新規発症1型糖尿病における低用量インターロイキン2：DIABIL-2第2b相試験から得られた知見 https://news.medxy.ai/vi/80742-2/Medxy AIvi2026-10-05T05:06:02-07:00Sử dụng Interleukin-2 liều thấp ở bệnh nhân mới được chẩn đoán mắc đái tháo đường tuýp 1: Những thông tin từ thử nghiệm lâm sàng giai đoạn 2b DIABIL-2 https://news.medxy.ai/low-dose-interleukin-2-in-newly-diagnosed-type-1-diabetes-insights-from-the-diabil-2-phase-2b-trial/Medxy AIen2026-10-05T05:05:43-07:00Low-Dose Interleukin-2 in Newly Diagnosed Type 1 Diabetes: Insights from the DIABIL-2 Phase 2b Trial https://news.medxy.ai/zh/no-touch-vs-traditional-vein/Medxy AIzh2026-10-05T05:05:07-07:00冠脉搭桥中无接触法与传统静脉获取：SWEDEGRAFT七年随机试验解读 https://news.medxy.ai/ja/no-touch-cabg-results/Medxy AIja2026-10-05T05:04:42-07:00CABGにおける no-touch 法は本当に優れているのか？ SWEDEGRAFT試験が示した7年成績 https://news.medxy.ai/vi/no-touch-vein-harvesting/Medxy AIvi2026-10-05T05:04:18-07:00Kỹ thuật lấy tĩnh mạch no-touch hay thường quy trong CABG: Những phát hiện từ thử nghiệm ngẫu nhiên SWEDEGRAFT kéo dài 7 năm https://news.medxy.ai/no-touch-versus-conventional-vein-harvesting-in-coronary-bypass-surgery-insights-from-the-swedegraft-seven-year-randomized-trial/Medxy AIen2026-10-05T05:03:55-07:00No-Touch Versus Conventional Vein Harvesting in Coronary Bypass Surgery: Insights from the SWEDEGRAFT Seven-Year Randomized Trial https://news.medxy.ai/zh/80734-2/Medxy AIzh2026-10-05T05:03:13-07:00心力衰竭中的心血管-肾脏-代谢多病共存：患病率、对预后的影响及按射血分数表型划分的临床意义 https://news.medxy.ai/ja/heart-failure-multimorbidity/Medxy AIja2026-10-05T05:02:48-07:00心不全における心血管・腎臓・代謝の多疾患併存：有病率、予後への影響、駆出率表現型別の臨床的意義 https://news.medxy.ai/vi/cardiorenal-metabolic-failure/Medxy AIvi2026-10-05T05:02:19-07:00Đa bệnh lý tim mạch–thận–chuyển hóa trong suy tim: Tỷ lệ hiện mắc, ý nghĩa tiên lượng và hàm ý lâm sàng theo các kiểu hình phân suất tống máu https://news.medxy.ai/cardiovascular-kidney-metabolic-multimorbidity-in-heart-failure-prevalence-prognostic-impact-and-clinical-implications-across-ejection-fraction-phenotypes/Medxy AIen2026-10-05T05:01:54-07:00Cardiovascular-Kidney-Metabolic Multimorbidity in Heart Failure: Prevalence, Prognostic Impact, and Clinical Implications Across Ejection Fraction Phenotypes https://news.medxy.ai/zh/immunotherapy-liver-cancer/Medxy AIzh2026-10-05T05:01:02-07:00免疫检查点抑制剂助力肝细胞癌降期：证据、结局与临床启示 https://news.medxy.ai/ja/80728-2/Medxy AIja2026-10-05T05:00:41-07:00免疫チェックポイント阻害薬による肝細胞癌のダウンステージング：エビデンス、転帰、および臨床的示唆 https://news.medxy.ai/vi/80727-2/Medxy AIvi2026-10-05T05:00:17-07:00Các thuốc ức chế điểm kiểm soát miễn dịch hỗ trợ hạ giai đoạn ung thư biểu mô tế bào gan https://news.medxy.ai/immune-checkpoint-inhibitor-based-downstaging-therapy-for-hepatocellular-carcinoma-evidence-outcomes-and-clinical-perspectives/Medxy AIen2026-10-05T04:59:51-07:00Immune Checkpoint Inhibitor-Based Downstaging Therapy for Hepatocellular Carcinoma: Evidence, Outcomes, and Clinical Perspectives https://news.medxy.ai/zh/racial-ethnic-disparities-face-paralysis/Medxy AIzh2026-10-05T04:39:12-07:00面瘫中的种族与族裔差异：诊断、合并症与治疗不平等 https://news.medxy.ai/ja/facial-paralysis-disparities/Medxy AIja2026-10-05T04:38:52-07:00顔面麻痺における人種・民族差：診断、併存疾患、治療アクセスの格差 https://news.medxy.ai/vi/racial-ethnic-disparities-facial-paralysis/Medxy AIvi2026-10-05T04:38:33-07:00Chênh lệch theo chủng tộc và sắc tộc trong liệt mặt: chẩn đoán, bệnh đồng mắc và bất công trong điều trị https://news.medxy.ai/racial-and-ethnic-disparities-in-facial-paralysis-diagnosis-comorbidities-and-treatment-inequities/Medxy AIen2026-10-05T04:38:14-07:00Racial and Ethnic Disparities in Facial Paralysis: Diagnosis, Comorbidities, and Treatment Inequities https://news.medxy.ai/zh/neck-hematoma-hypocalcemia-risk/Medxy AIzh2026-10-05T04:37:35-07:00甲状腺切除术后颈部血肿提示更高低钙血症风险：基于全国外科数据库53,091例病例的研究洞见 https://news.medxy.ai/ja/neck-hematoma-hypocalcemia-risk-2/Medxy AIja2026-10-05T04:37:16-07:00甲状腺摘出術後の頸部血腫は低カルシウム血症リスクを高める：全国手術データベース53,091例からの知見 https://news.medxy.ai/vi/neck-hematoma-thyroidectomy/Medxy AIvi2026-10-05T04:36:55-07:00Máu tụ vùng cổ sau cắt tuyến giáp báo hiệu nguy cơ hạ calci máu cao hơn: Phân tích từ 53.091 ca trong cơ sở dữ liệu phẫu thuật quốc gia https://news.medxy.ai/post-thyroidectomy-neck-hematoma-predicts-higher-risk-of-hypocalcemia-insights-from-53091-cases-in-a-national-surgical-database/Medxy AIen2026-10-05T04:36:36-07:00Post-Thyroidectomy Neck Hematoma Predicts Higher Risk of Hypocalcemia: Insights from 53,091 Cases in a National Surgical Database https://news.medxy.ai/zh/rectal-cancer-lymph-node-management/Medxy AIzh2026-10-05T04:35:50-07:00直肠癌TNT后侧盆腔淋巴结降期患者的管理策略：是否仍需一味手术清扫？ https://news.medxy.ai/ja/lateral-pelvic-lymph-nodes/Medxy AIja2026-10-05T04:35:30-07:00全補助療法後にダウンステージングされた直腸癌の側方骨盤リンパ節：管理戦略の再考 https://news.medxy.ai/vi/pelvic-lymph-node-management/Medxy AIvi2026-10-05T04:35:08-07:00Tái đánh giá chiến lược xử trí hạch bạch huyết chậu bên đã giảm giai đoạn trong ung thư trực tràng dưới liệu pháp tân bổ trợ toàn diện https://news.medxy.ai/reevaluating-management-strategies-for-downstaged-lateral-pelvic-lymph-nodes-in-rectal-cancer-under-total-neoadjuvant-therapy/Medxy AIen2026-10-05T04:34:49-07:00Reevaluating Management Strategies for Downstaged Lateral Pelvic Lymph Nodes in Rectal Cancer under Total Neoadjuvant Therapy